Shoulder Innovations posts 38% Q3 revenue growth and lifts 2026 outlook

Shoulder Innovations reported third‑quarter 2026 net revenue of $16.2 million, a 38% year‑over‑year increase, and gross margin of 78.5%. The company sold 2,126 implant systems, launched the InSet Go glenoid implant and received FDA 510(k) clearance for the N‑22 humeral head. It raised its full‑year 2026 net‑revenue guidance to $68 million‑$70 million and announced a settlement with Catalyst OrthoScience and a promotion of Jon Osborne to chief commercial officer.

The raised full‑year revenue guidance signals stronger demand and may support a higher valuation for the company (the company expects the $68‑$70 million range, up from $67‑$69 million). The new product launches and settlement clear regulatory and litigation risks, potentially improving future cash flows.

  • 1Third‑quarter 2026 net revenue was $16.2 million, up 38% from the same quarter in 2025.
  • 2Gross margin for the quarter was 78.5%, compared with 76.2% a year earlier.
  • 3The company sold 2,126 implant systems in Q3, a 34% increase year‑over‑year.
  • 4Full‑year 2026 net‑revenue guidance was raised to $68 million‑$70 million, representing 44%‑48% growth over 2025.
  • 5Cash, cash equivalents and marketable securities totaled $92.3 million as of September 30, 2026.
  • 6The company received FDA 510(k) clearance for the N‑22 humeral head and launched the InSet Go glenoid implant.

Sources